The University of Texas MD Anderson Cancer Center and Amgen today announced two multi-year collaboration agreements aimed at accelerating development of a variety of Amgen’s early-stage oncology therapies for patients with leukemia, myelodysplastic syndromes, multiple myeloma, small-cell lung cancer, and other non-lung cancers with small-cell histologies. The agreements combine Amgen therapies nearing clinical development or those that have already begun the process with MD Anderson’s translational medicine capabilities.
The collaborations will focus on Amgen’s bispecific T cell engager (BiTE®), chimeric antigen receptor (CAR) T cell and small molecule programs. Amgen is advancing both types of T cell therapies against different targets and, in some cases, the same target. BiTE® antibody constructs and CAR T cell therapies differ in their approach, though they share the same goal – activating a patient’s immune system to eradicate cancer. BiTE® antibody constructs work by bridging T cells to tumor cells, enabling them to attack tumor cells, while CAR T cell therapies reengineer a patient’s own T cells to recognize tumor-specific antigens, inciting an immune system attack against cancer cells.
“The field of immuno-oncology is rapidly evolving and combining resources from both organizations could be important in answering key scientific questions,” said Patrick Hwu,
Article originally posted at